FiercePharma2h
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
PipelineReview.com7h
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
STAT7h
More evidence on GLP-1s and opioid addiction
In a new study examining people with opioid or alcohol use disorder, prescriptions for Ozempic, Wegovy, Mounjaro, and ...
The Pharma Letter22h
Chengdu Baiyu enters into a license deal with Novartis
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...
FierceBiotech1d
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
ENDPOINTS NEWS1d
No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...
The Pharma Letter1d
FDA guidance for reconsideration at the division level under GDUFA
The US Food and Drug Administration (FDA) yesterday published the guidance for industry, “Requests for Reconsideration at the ...